Publication
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugSunitinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38354330
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Alteration + FGFR2 AlterationFGFR1FGFR21 | ||||||||
| Sunitinib | Malignant Breast Neoplasm | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11883In this phase II clinical trial, 40 patients with breast cancer harboring either FGFR1 or FGFR2 alterations (amplifications or mutations) were recruited. Of the 40 patients, 30 had FGFR1 alterations (… (full text at CIViC) PMID 38354330 · Calfa et al., 2024 · Open in CIViC | civic |
| FGFR1 Amplification1 | ||||||||
| Sunitinib | Malignant Breast Neoplasm | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID12479The Targeted Agent and Profiling Utilizing Registry (TAPUR) study is a prospective, phase II, basket trial that aims to evaluate the antitumor activity of commercially available targeted therapies pre… (full text at CIViC) PMID 38354330 · Calfa et al., 2024 · Open in CIViC | civic |